The Ryan Haight Act and Telehealth Ketamine
The Ryan Haight Act is the federal law at the center of every discussion about telehealth controlled substance prescribing. Understanding its history, its provisions, and how it has been navigated illuminates why the telehealth ketamine industry operates the way it does and what risks the regulatory future holds.
The Story Behind the Law
Ryan Haight was a 18-year-old from La Mesa, California, who died in 2001 from an overdose of Vicodin obtained through an online pharmacy. He had received a prescription via the internet from a physician who had never evaluated him in person. His death became a catalyst for federal legislation targeting the prescribing of controlled substances through online pharmacies without proper medical oversight.
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was passed with bipartisan support. Its legislative intent was clearly to prevent the type of pill mill prescribing that led to Ryan's death. The law was not primarily designed with telehealth in mind—in 2008, telemedicine was a nascent field. But its provisions created the legal architecture that would later become the central regulatory challenge for telehealth ketamine.
Core Provisions of the Act
The In-Person Evaluation Requirement
The Act's most consequential provision for telehealth: a practitioner who prescribes a controlled substance via the internet must have first conducted at least one in-person medical evaluation of the patient. The in-person evaluation must be at a location where the practitioner is physically present and the patient physically presents.
Definition of "Prescribing by Means of the Internet"
The Act broadly defined internet-facilitated prescribing to include prescriptions issued based on an online questionnaire or conversation "that does not consist of an in-person medical evaluation." This encompassed virtually all telehealth prescribing of controlled substances.
Exceptions to the In-Person Requirement
The Act created limited exceptions:
- Hospital or clinic-based telemedicine where a practitioner is physically present at the patient's location
- Indian Health Service telemedicine
- State-based telemedicine programs meeting specific criteria
- Specialized settings with in-person clinician oversight
None of these exceptions applied to a patient at home connecting to a remote physician via video—the core telehealth ketamine model.
The Act's Effect on Telehealth Ketamine
From 2008 until the COVID-19 emergency in 2020, the Ryan Haight Act effectively barred the direct-to-consumer at-home ketamine model. While in-person IV ketamine clinics could serve patients on-site, no legitimate provider could evaluate a patient via video and send them home with a ketamine prescription without first seeing them in person.
Some workarounds were attempted—requiring an initial in-person visit before the telehealth relationship began—but these significantly limited the convenience and accessibility that telehealth is designed to provide.
The COVID-19 Transformation
The March 2020 public health emergency declaration changed everything. The DEA invoked its emergency authority to waive the Ryan Haight in-person requirement for the duration of the emergency. Suddenly, practitioners could conduct the entire evaluation and prescribing relationship via video—including for controlled substances.
The telehealth ketamine industry emerged almost immediately. Companies launched in 2020 and 2021, building business models on the assumption that these exemptions would either become permanent or be replaced by a workable permanent framework. Our guide to how telehealth ketamine works describes the care model that developed during this period.
The Debate Following COVID
As the public health emergency ended, the central question became: what replaces the exemptions?
Industry Position
The telehealth ketamine industry and broader telehealth advocates argued that the COVID experience had demonstrated that appropriate controlled substance prescribing could be conducted via telehealth with good outcomes and without the diversion harms that the Ryan Haight Act was designed to prevent. They called for permanent flexibilities that preserved telehealth access.
DEA's Initial Response
The DEA's 2023 proposed rules were widely seen as too restrictive—particularly the 30-day prescription limit and the requirement for in-person evaluation before continuation prescriptions. The proposed rules would have significantly disrupted the telehealth ketamine model and generated the largest public comment response the DEA had ever received for a proposed rule.
The Ongoing Tension
The fundamental tension in the post-Ryan Haight debate is about risk models. The Ryan Haight Act was a response to a real problem—inappropriate prescribing of opioids without clinical evaluation. The DEA's instinct to maintain in-person evaluation requirements reflects a legitimate concern about controlled substance safety. But the telehealth ketamine industry argues that the risk profile of sublingual ketamine at therapeutic doses in screened patients is fundamentally different from opioid diversion, and that in-person evaluation requirements impose costs that fall primarily on the most vulnerable patients (those without transportation, in rural areas, with disabilities) who have the most to gain from telehealth access.
Where the Debate Stands Today
As of early 2025, the Ryan Haight Act has not been formally amended. The DEA's COVID exemptions remain in effect as extensions, providing the current legal basis for telehealth ketamine. The permanent rulemaking process is ongoing, with a new round of proposed rules expected.
The debate continues on three fronts:
- Administrative rulemaking: What will the permanent framework look like?
- Congressional action: Will Congress amend the Ryan Haight Act to create a statutory framework for telemedicine controlled substance prescribing?
- Litigation: Could the DEA's approach to the extensions or the permanent rules be challenged in court?
The outcome of these three tracks will determine whether the telehealth ketamine model survives and thrives or faces significant disruption. Our future of regulations guide examines the most likely scenarios.
What the Ryan Haight History Teaches
For patients and advocates, the Ryan Haight Act's history offers an important lesson: regulatory frameworks designed for one problem can create unintended barriers to beneficial innovation. The Act was designed to stop pill mills, not to block telehealth mental health care. The challenge going forward is shaping a permanent framework that addresses the legitimate concerns about controlled substance diversion while preserving the genuine access benefits that telehealth has demonstrated.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
- SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
Share